Sign in

Dr Matteo Fabbri

@drmatteofabbri.bsky.social
97 followers 92 following 40 posts

Advanced HF and pulmonary hypertension cardiologist . My opinions are my own.

PostsRepliesMedia
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 30/04/2025
Dr Bilgili showed us the outcomes after OHTx divided by need of ECMO at 72 hours post surgery. ECMO need at 72 hours greatly worsens survival.
020
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 30/04/2025
Dr Huang shows pre and post allocation change status change in immunosuppression and outcomes among multi-organ transplant. Super interesting data. @ishlt.bsky.social #ISHLT2025
020
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 30/04/2025
Dr Elbert Heng shows amazing study on survival of patients with ACHD receiving OHTx vs multiorgan transplant alone. ❤️ and 🫁 carry the worse survival so far. @ishlt.bsky.social #ISHLT2025
020
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 30/04/2025
Dr Paula Ramirez shows us their new predictive models to discriminate if ❤️ and kidney transplant is superior to kidney after ❤️. Beautiful work which can help change clinical practice at #ISHLT2025 @ishlt.bsky.social
020
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 30/04/2025
Amazing work presented from Dr Topkara who developed a kidney risk score which predicts the risk for AKI/HD after ❤️ transplant! High AUC, higher than eGFR alone! #ISHLT2025 @ishlt.bsky.social
020
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 30/04/2025
Dr Hussain showed us a single center experience of Fontain patients receiving ❤️ transplant. Should they get a liver as well? Seems like all 24 of them had recovery of the liver function after transplant without needing a a new liver. Great science at #ISHLT2025 @ishlt.bsky.social
010
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 30/04/2025
Finally we talk about induction with Dr Barten. To induce or not to induce? This is the dilemma! And Dr Carboni showed us how AI can be implemented in helping us with HLA matching.
000
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 30/04/2025
It’s AB0ut time we talk with Dr Aversa about AB0! Super interesting case of an 0 patient receiving nonA1 🫁 transplant with no signs of rejections. Incredible science showed at #ISHLT2025 @ishlt.bsky.social
010
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 30/04/2025
Followed by Dr Guillaime Coutance guiding us through PRAs. Which antibodies should we look for and how to measure??? Dr Lyster showed us what to do with highly sensitised patients pre and post transplant. #ISHLT2025
000
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 30/04/2025
And last day at #ISHLT2025 we go through the consensus statement with Dr Annette Jackson. Amazing talk on the use of antibodies in transplant. @ishlt.bsky.social
011
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 28/04/2025
We finish with a great talk from the amazing @nickbruin.bsky.social about the Delphi consensus. Refer early and often Reassess your patient. 🫁 transplant save lives and improves quality of life in PAH #PAH #PH #lungtransplant #ISHLT2025 @ishlt.bsky.social onlinelibrary.wiley.com/doi/full/10....
onlinelibrary.wiley.com
Approach to Lung Transplantation in Pulmonary Arterial Hypertension: A Delphi Consensus on Behalf of the Transplant Task Force of the Pulmonary Vascular Research Institute
Lung transplantation is indicated for selected patients with advanced pulmonary arterial hypertension (PAH). We used a modified Delphi process to develop recommendations on care of patients with PAH ...
052
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 28/04/2025
What is the role of MCS in PAH and cardiogenic shock? 1) patient selection 2) choose the RIGHT access 3) have an exit strategy in view 4) start PH therapies 5) consider transplant These are few of the points we discussed today with Dr Sommer @ishlt.bsky.social #ISHLT #PAH #PH
010
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 28/04/2025
What can you do when a patient with PH land in the ICU with Shock? Dr Mads Andersen walks us through Preload treatment Inotropes and its use Afterload for PH Important talk @ishlt.bsky.social #ISHLT2025 #PH
010
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 28/04/2025
And from the Right Ventricle- Right atria interaction we move to the complex relationship between heart - kidneys and lungs in PH with an amazing talk from Dr. Rosenkranz. #ISHLT2025 #PAH #PH @ishlt.bsky.social
020
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 28/04/2025
Today we dig deep in the pathophys of PH #ISHLT2025 with Dr Frances De Man on pressure loop of the RA. Super interesting discussion on what happens to myocites in the right atrium. @ishlt.bsky.social #PAH #PH
010
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 27/04/2025
Today @ishlt.bsky.social in Boston we talked about Pulmonary Hypertension. Here the main take-away from the Updates on the 7th World Symposium.
532
Reposted by Dr Matteo Fabbri
Eric Topol @erictopol.bsky.social · 07/04/2025
In people with diabetes, GLP-1 and SGLT2i drugs were associated with less Alzheimer's disease and related dementias jamanetwork.com/journals/jam...
518545
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 31/03/2025
Another study on the striking effect of sotatercept in PAH patients with elevated REVEAL score. Findings are not subtle at all! Trial stopped early with composite outcome of death, 🫁 transplant or hospitalization HR 0.24 (95%CI 0.13-0.43) www.nejm.org/doi/full/10....
nejm.org
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death | NEJM
Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension. The eff...
010
Reposted by Dr Matteo Fabbri
American College of Cardiology @accintouch.bsky.social · 29/03/2025
DAPA-TAVI: The #SGLT2 inhibitor dapagliflozin was superior to standard care alone in decreasing rates of all-cause mortality or worsening #HeartFailure in older adults w/ #vhdAS undergoing TAVI, resulting in a 28% relative risk ↘️. #ACC25 More: bit.ly/4cfLNsy #cvSurg #CardioSky #MedSky
11610
Reposted by Dr Matteo Fabbri
Eric Topol @erictopol.bsky.social · 24/03/2025
Of >105,000 participants with 30-year follow-up, only 9.3% achieved healthy aging (age 70, w/o any chronic diseases). Their diet was significantly associated with this outcome. @naturemedicine.bsky.social
20453112
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 22/03/2025
Vutrisiran is now approved for aTTR cardiac amyloid! Another medication to help these patients! www.businesswire.com/news/home/20...
businesswire.com
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis wi...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of ...
010
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 04/01/2025
Linguine with mussels. ❤️
000
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 23/12/2024
Check out this paper from Sweden. Long term use of LDL lowering meds and anti-HTN meds was associated with lower the odds of dementia in this case-control study. No reason not to lower BP and cholesterol. alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
alz-journals.onlinelibrary.wiley.com
Use of common cardiovascular disease drugs and risk of dementia: A case–control study in Swedish national register data
INTRODUCTION Cardiovascular drug use may help prevent dementia; however, current evidence is mixed. Using a case–control design, we investigated the association between duration and combination of m...
000
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 14/12/2024
I’ll diet on Monday… Chocolate chip cookies 🍪🍪🍪🍪
000
Reposted by Dr Matteo Fabbri
International Society for Heart and Lung Transplantation (ISHLT) @ishlt.bsky.social · 13/12/2024
Happy #FridayThe13th - and if you're transplanting, fear not! This research group found no superstitious effect of Friday the 13ths or Full Moons on cardiac transplant outcomes, acuity, and volume. #JHLT #heartTx #cardiosky #transplantsky @uofpenn.bsky.social www.jhltonline.org/article/S105...
Goodnight Moon, The (not so) Mystical Effect of Folklore and Superstitions on Cardiac Transplantation
Do Friday the 13ths or Full Moons negatively impact heart transplants? Does volume increase on these "unlucky" days?

Slide shows study design and findings, which can be read at the link in the post.
042
Reposted by Dr Matteo Fabbri
National Lipid Association @nationallipid.bsky.social · 10/12/2024
🚨 Big news in lipidology! 🚨 @newamsterdampharma.bsky.social's Phase 3 BROADWAY trial results for Obicetrapib are in: ✅ 33% LDL-C reduction at day 84 (vs placebo) ✅ 21% reduction in MACE after 1 year A promising advance for patients with #ASCVD & HeFH! #Cardiology #Lipidology
1123
Reposted by Dr Matteo Fabbri
Parham Eshtehardi MD @cardioobdoc.bsky.social · 04/12/2024
Simgle combined measure of hsCRP, LDL & Lp(a) among initially healthy U.S. women was predictive of incident CV events during a 30-yr period #CardioSky #MedSky #NEJM @drmarthagulati.bsky.social @erinmichos.bsky.social @michaeldshapiro.bsky.social @drlipid.bsky.social www.nejm.org/doi/full/10....
0138
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 04/12/2024
Could not make it to AHA2024? Check out the HF highlights from @jcardfail.bsky.social. So great to be included in this. @robmentz.bsky.social @dranulala.bsky.social onlinejcf.com/article/S107...
031
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 02/12/2024
Echocardiogram is very important in diagnosing and managing pulmonary hypertension, but it could be very discrepant with the RHC especially if there not enough TR. Here you see the TR jet velocity of a young patient with hereditary PAH and next to it the RHC pressure curve in the PA.
110
Reposted by Dr Matteo Fabbri
Parham Eshtehardi MD @cardioobdoc.bsky.social · 28/11/2024
Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk & Procedural Complexity 🦋 Clopidogrel monotherapy was associated with lower thrombotic & bleeding risks #CardioSky #MedSky @jama.com jamanetwork.com/journals/jam...
0137
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 20/11/2024
A staple in every italian kitchen. The first thing we do in the morning and the last one at night;) ☕️ #coffee
020
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 17/11/2024
Presented @ AHA2024. Very impressed with the results. Hope to read the full article soon. www.nejm.org/doi/full/10....
nejm.org
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | NEJM
Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor...
000
Dr Matteo Fabbri @drmatteofabbri.bsky.social · 17/11/2024
Hey bluesky, this is Osvaldo. He loves chasing anything that moves, eating, snuggling and purring. And if you look at him very closely, he has the cutest smile. 🐱❤️
010